E. Ohman J or Asset Management AB Buys 18,012 Shares of DexCom, Inc. $DXCM

E. Ohman J or Asset Management AB increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 113,204 shares of the medical device company’s stock after acquiring an additional 18,012 shares during the period. E. Ohman J or Asset Management AB’s holdings in DexCom were worth $7,624,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in DexCom during the 4th quarter worth about $483,356,000. AQR Capital Management LLC lifted its holdings in shares of DexCom by 597.8% in the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after purchasing an additional 2,658,158 shares in the last quarter. Employees Provident Fund Board bought a new stake in shares of DexCom in the fourth quarter valued at about $145,352,000. J. Stern & Co. LLP boosted its position in shares of DexCom by 2,114.8% during the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock worth $106,323,000 after buying an additional 1,529,641 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of DexCom by 271.4% during the first quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock worth $129,699,000 after buying an additional 1,509,219 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $87.65 on Tuesday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company has a market cap of $33.08 billion, a PE ratio of 34.64, a price-to-earnings-growth ratio of 1.42 and a beta of 1.41. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $88.18. The business’s 50 day moving average price is $74.68 and its two-hundred day moving average price is $69.85.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter in the prior year, the business earned $0.48 EPS. The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. On average, analysts predict that DexCom, Inc. will post 2.65 EPS for the current year.

Insider Transactions at DexCom

In related news, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. The trade was a 7.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares in the company, valued at approximately $27,538,704. This represents a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 101,494 shares of company stock worth $7,475,168 over the last three months. Company insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on DXCM shares. Barclays reissued an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Citigroup reaffirmed a “buy” rating and set a $88.00 price target (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Truist Financial set a $93.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Weiss Ratings lowered shares of DexCom from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. Finally, UBS Group set a $96.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.